Daniel J. Freeman

发表

London low emission zone feasibility study phase II: a summary of the phase two report

Julian Allen, Michael Browne, Steve Pye, 2003 .

London low emission zone feasibility study phase II: final report to the London low emission zone steering group

Julian Allen, Paul Watkiss, Stephen Anderson, 2003 .

2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.

Daniel J. Freeman, V. Viswanadhan, Q. Zeng, 2010, Bioorganic & medicinal chemistry letters.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Daniel J. Freeman, E. Van Cutsem, S. Patterson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTEN Regulates Mdm2 Expression through the P1 Promoter*

Daniel J. Freeman, Chun-Ju Chang, Hong Wu, 2004, Journal of Biological Chemistry.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, Todd Juan, T. Bush, 2009, Molecular Cancer Therapeutics.

PTEN Deletion Leads to Up-regulation of a Secreted Growth Factor Pleiotrophin*

Daniel J. Freeman, Hong Wu, Yanying Huo, 2006, Journal of Biological Chemistry.

Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.

Daniel J. Freeman, P. Harari, D. Wheeler, 2008, International journal of radiation oncology, biology, physics.

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

Daniel J. Freeman, Sameer Doshi, R. Radinsky, 2012, Molecular Cancer.

Azole-based inhibitors of AKT/PKB for the treatment of cancer.

Daniel J. Freeman, Q. Zeng, Guomin Yao, 2010, Bioorganic & medicinal chemistry letters.

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells.

Daniel J. Freeman, Des C. Jones, B. Tran, 2021, Cancer discovery.

Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models 1

Daniel J. Freeman, M. Boedigheimer, M. Damore, 2013 .

7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy

Daniel J. Freeman, S. Patterson, S. Siena, 2007 .

Panitumumab (pmab) efficacy and patient-reported outcomes in metastatic colorectal cancer patients with wild-type KRAS tumor status.

Daniel J. Freeman, M. Peeters, S. Siena, 2008 .

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.

Daniel J. Freeman, R. Wahl, J. McCarter, 2011, Journal of medicinal chemistry.

Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2012, Journal of medicinal chemistry.

Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2011, Journal of medicinal chemistry.

Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors

Daniel J. Freeman, M. Rothe, R. Radinsky, 2008 .

Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer

Daniel J. Freeman, 2009 .

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Daniel J. Freeman, J. Berlin, J. Hecht, 2008, Clinical colorectal cancer.

Optimizing oncolytic virotherapy in cancer treatment

Daniel J. Freeman, K. Harrington, J. Soria, 2019, Nature Reviews Drug Discovery.

Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2012, Bioorganic & medicinal chemistry letters.

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Hong Wu, Daniel J. Freeman, Robert D Cardiff, 2003, Cancer cell.

Genetic background controls tumor development in PTEN-deficient mice.

Daniel J. Freeman, M. Groszer, Hong Wu, 2006, Cancer research.

Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.

Daniel J. Freeman, M. Boedigheimer, M. Damore, 2013, Neoplasia.

A comparability study of 5 commercial KRAS tests

Daniel J. Freeman, I. Sarosi, S. Patterson, 2010, Diagnostic pathology.

Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.

Daniel J. Freeman, J. McCarter, D. Whittington, 2012, Journal of medicinal chemistry.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

Daniel J. Freeman, Z. Tsuchihashi, J. von Pawel, 2015, EBioMedicine.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Daniel J. Freeman, J. Crawford, D. Prager, 2013, Journal of Thoracic Oncology.

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue

Daniel J. Freeman, R. Beckman, Xiaoping Jin, 2017, Biomarker insights.

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.

Daniel J. Freeman, Hongyu Liao, Nancy Zhang, 2011, Journal of medicinal chemistry.

309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models

Daniel J. Freeman, M. Rothe, R. Radinsky, 2008 .

Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo

Daniel J. Freeman, S. Hartmann, M. Rothe, 2008 .

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

Daniel J. Freeman, J. Berlin, J. Hecht, 2007 .

Comparability testing of KRAS mutations and association with efficacy from a phase 3 randomized trial of panitumumab (pmab)

Daniel J. Freeman, E. Van Cutsem, I. Sarosi, 2009 .

Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies

Daniel J. Freeman, P. Chattopadhyay, D. Simeone, 2023, Frontiers in Immunology.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Daniel J. Freeman, E. Van Cutsem, R. Radinsky, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells

Daniel J. Freeman, Des C. Jones, G. Browne, 2018, Immunology.

Abstract B171: U3‐1287 (AMG 888), a fully human anti‐HER3 mAb, demonstrates in vitro and in vivo efficacy in NSCLC models

Daniel J. Freeman, R. Radinsky, Matthias Schneider, 2009 .

The Influence of Sodium Glycocholate and Other Additives on the in vivo Transfection of Plasmid DNA in the Lungs

Daniel J. Freeman, R. Niven, 1996, Pharmaceutical Research.